In accordance with FAR subpart 6.302-1(c) (ii), the Centers for Disease Control and Prevention (CDC) intends to issue a sole purchase order to Qiagen Inc. for the Pyrosequencer. This purchase request is for a PyroMark96 ID Pyrosequencer unit and accessories. The Qiagen corporation is the sole U.S. distributer for these instruments and the necessary reagents. The Pyrosequencing system is a novel proprietary technology widely employed in infectious disease clinical service and research. The platform is widely adapted with multiple units in place at the CDC for tracking pandemic influenza, at the biotechnology core facility, etc. This instrument is being acquired for use for a new clinical assay to be available from the CDC later this year. The PyroMark96 ID system is slated for use in the Division of Tuberculosis Elimination's (DTBE) flagship project: Rapid Detection of Drug-Resistant (RDDR) TB in Persons at High Risk. This flagship project is described and the technology chosen by an outside panel for the CDC: http://www.cdc.gov/tb/topic/laboratory/rapidmoleculartesting/default.htm It is the understanding of the Government that an award to any other source would cause unacceptable delays in meeting the requirements of the Government. Interested parties who feel that they possess the capabilities to provide the services described above should submit a capability statement demonstrating their abilities to provide the services. The information received in response to this notice will be considered solely for the purpose of determining whether or not to conduct a competitive requirement. Please send your documentation to Deborah Workman by fax (770) 488-2889, or email to
[email protected]. Documentation should be received within fifteen (15) days after the date of publication of this synopsis to be considered by CDC. A determination by the CDC not to compete this proposed contract, based upon responses to this notification, is solely within discretion of the government.